Kairos Pharma financials
$1.66−1.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$5.6M | -$2.3M |
| Net income | -$5.4M | -$2.6M |
| Net margin | — | — |
| Diluted EPS | $-2.10 | $-1.61 |
| EBITDA | -$3.2M | -$2.2M |
| Operating cash flow | -$3.4M | -$4.0M |
| Free cash flow | -$3.4M | -$4.0M |
| Diluted shares | 2.6M | 1.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $4.5M | $1.3M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $6.5M | $5.8M |
| Total liabilities | $199.0K | $992.0K |
| Shareholders' equity | $6.3M | $4.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology